COPD clinical trials

Resting O2

  • Lancet 1981
  • resting O2 reduces mortality for pts with resting hypoxemia spO2<88
  • LOTT trial 2016: no decrease in time to death or time to hospitalization

Uplift

  • UPLIFT 2008
  • tiotopium relieves dyspnea, improves lung function, quality of life, reduces exacerbation
  • no significant difference in FEV1 decline or mortality

Torch

  • TORCH 2007
  • ICS/LABA improved lung function with FEV1 vs placebo vs LABA vs ICS
  • no mortality benefit with combination therapy

React

  • REACT 2015
  • triple therapy with Roflumulast (long acting PDE4 inhibitor)
  • population: severe COPD, chronic bronchitis, and at least 2 exacerbations
  • significant reduction in exacerbations
  • increased side effects: diarrhea, nausea, decreased appetite

Albert

  • Albert 2011
  • Chronic azithromycin
  • population: pts with mod-severe COPD and either continuous O2 or at least one exacerbation in last year